William Blair analyst Andy Hsieh has reiterated their neutral stance on NKTR stock, giving a Hold rating on November 5.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Andy Hsieh’s rating is based on several factors, primarily revolving around the ongoing clinical trials and their potential outcomes. Nektar Therapeutics is currently conducting the Phase IIb REZOLVE-AA trial for rezpeg in alopecia areata, with results anticipated in December. Additionally, the company is preparing for an End-of-Phase-II meeting with the FDA to discuss the Phase III development of rezpeg for atopic dermatitis, with a trial expected to begin in the first half of 2026.
Despite promising data from the REZOLVE-AD Phase IIb study, rezpeg’s efficacy appears comparable to the OX40 drug class but lower than Dupixent, a leading competitor. The chronic nature of atopic dermatitis and the high frequency of moderate injection site reactions could pose commercial challenges. However, if rezpeg shows a remittive effect, it might offset these concerns. These uncertainties contribute to the Hold rating, as investors await further data to clarify rezpeg’s market potential.
In another report released on November 5, TR | OpenAI – 4o also reiterated a Hold rating on the stock with a $55.00 price target.
Based on the recent corporate insider activity of 20 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of NKTR in relation to earlier this year.